Physicochemical Treatment of Hazardous Wastes[危险废物物化处理法]00

合集下载

壳聚糖和聚丙烯酸吸附重金属

壳聚糖和聚丙烯酸吸附重金属

壳聚糖和聚丙烯酸吸附重金属引言重金属污染对环境和生物健康造成了严重影响,因此,寻找有效的重金属去除方法具有重要意义。

壳聚糖和聚丙烯酸作为一种常用的吸附材料,具有良好的吸附性能,被广泛应用于重金属去除领域。

本文将介绍壳聚糖和聚丙烯酸在吸附重金属方面的研究进展。

壳聚糖在吸附重金属中的应用壳聚糖是一种天然产物,由壳类动物的外壳中提取得到。

壳聚糖具有多种功能官能团,如氨基(-NH2)、羟基(-OH)和甲氧基(-OCH3),这些官能团使其具有良好的吸附性能。

壳聚糖通过静电吸附、配位作用和表面吸附等机制与重金属离子结合,形成稳定的络合物或沉淀。

研究发现,壳聚糖对各种重金属离子具有高度选择性,特别是对汞、铅和铬等有害重金属离子的吸附效果显著。

此外,壳聚糖的吸附性能受到pH值、温度、初始离子浓度和壳聚糖颗粒大小等因素的影响。

一些研究还探讨了壳聚糖改性和复合材料的制备方法,以进一步提高其吸附性能。

聚丙烯酸在吸附重金属中的应用聚丙烯酸是一种合成聚合物,具有多个羧酸官能团(-COOH),这些官能团可以与重金属离子形成络合物或离子交换反应。

聚丙烯酸通过静电吸附和配位作用等机制吸附重金属离子,具有较高的吸附容量和选择性。

研究表明,聚丙烯酸在吸附重金属方面的性能受到溶液pH 值、温度、初始离子浓度和聚丙烯酸颗粒大小的影响。

较低的溶液pH值有利于聚丙烯酸与重金属离子形成络合物,而较高的溶液pH值则促进离子交换反应。

此外,一些研究还探索了聚丙烯酸改性和复合材料的制备方法,以提高其吸附性能和重复利用性。

壳聚糖与聚丙烯酸的复合应用由于壳聚糖和聚丙烯酸各自具有良好的吸附性能,研究人员开始探索将两者进行复合应用的可能性。

壳聚糖和聚丙烯酸的复合材料不仅能够充分利用两者的吸附性能,而且还可以通过共存效应提高材料的吸附效果。

研究表明,壳聚糖和聚丙烯酸的复合材料在吸附重金属方面表现出优异的性能。

复合材料通常具有较大的比表面积和孔隙结构,提高了重金属离子的吸附速率和吸附容量。

化学品安全技术说明书英文缩写为

化学品安全技术说明书英文缩写为

COSHH SDS (Control of Substances Hazardous to Health Safety Data Sheet)IntroductionThe Control of Substances Hazardous to Health (COSHH) Safety Data Sheet (SDS) is an essential document for ensuring the safe handling, storage, and use of chemical substances in the workplace. The SDS provides detailed information about the chemical composition, potential hazards, and recommended safety precautions associated with the chemical product.Purpose of a COSHH SDSThe primary purpose of a COSHH SDS is to provide vital information to employers, employees, and emergency responders regarding the hazards and risks associated with the use of chemical substances. The SDS serves as a comprehensive guide to understanding the precautions that need to be taken to prevent accidents, injuries, and adverse health effects caused by exposure to hazardous chemicals.Key Components of a COSHH SDS1.Identification: This section includes the product name,manufacturer’s details, and emergency contact information.position/Ingredients: Detailed information about the chemicalcomponents present in the product along with their percentage compositions.3.Hazards Identification: This section outlines the potential hazardsassociated with the chemical substance, including physicochemical, health, and environmental hazards.4.First Aid Measures: Guidance on the necessary immediate steps tobe taken in case of accidental exposure or ingestion, including specificinstructions for different types of exposure (e.g., inhalation, skin contact, eyecontact).5.Firefighting Measures: Information on recommended extinguishingmethods, precautions to be taken, and hazards associated with fires involving the chemical substance.6.Accidental Release Measures: Procedures to be followed in theevent of a spill or release, including containment, cleaning, and disposalmeasures.7.Handling and Storage: Detailed instructions for safe handling,storage, and transportation of the chemical substance, including precautionsfor handling incompatible materials.8.Exposure Controls/Personal Protection: Information onengineering controls, personal protective equipment (PPE), and recommended exposure limits (if applicable).9.Physical and Chemical Properties: This section includesinformation on the physical and chemical properties of the substance, such as melting point, boiling point, solubility, etc.10.Stability and Reactivity: Information on the stability of thesubstance and its potential reactivity with other substances or environmental factors.11.Toxicological Information: Detailed information on the toxicologicalproperties of the chemical substance, including acute and chronic health effects, carcinogenicity, mutagenicity, and reproductive toxicity.12.Ecological Information: Information on the potential environmentalimpacts of the substance, including its persistence, bioaccumulation potential, and toxicity to aquatic life.13.Disposal Considerations: Guidelines for the safe disposal of thesubstance, including any specific regulatory requirements.14.Transport Information: Information on the safe transportation ofthe chemical substance, including any specific requirements or restrictions.15.Regulatory Information: Applicable regulatory and legalrequirements for the substance, including labeling and classification.16.Other Information: Additional information that may be relevant,such as references, date of preparation, and revision history.ConclusionThe COSHH Safety Data Sheet (SDS) is a vital tool in promoting the safe handling, storage, and use of hazardous chemical substances. The comprehensive information provided in the SDS allows employers, employees, and emergency responders to understand and mitigate the potential risks associated with these substances. By strictly adhering to the guidelines outlined in the SDS, organizations can ensure the safety and well-being of their employees while minimizing the environmental impact of chemical substances.。

水葫芦/污泥共热解法制备生物炭粒及其对Cr 3+ 的吸附特性

水葫芦/污泥共热解法制备生物炭粒及其对Cr 3+ 的吸附特性
adsorption mechanism. The leaching toxicity of water hyacinth∕sludge biochar particles was lowerꎬ which can provide a basis for the
selection of raw materials in the development of biochar as environmental and functional materials.
pyrolysis temperature. SEM images indicated that the specific surface areas of biochar particles were high and the tubular and pore
收稿日期: 2019 ̄05 ̄20 修订日期: 2019 ̄07 ̄29
water hyacinth and sludge at temperatures of 300ꎬ 400 and 500 ℃ . The basic physicochemical properties of biochar particles were studied
through the analysis of the yieldꎬ ash contentꎬ specific surface areaꎬ pore size analysis and scanning electron microscope ( SEM) analysis.
1.中国环境科学研究院ꎬ 环境基准与风险评估国家重点实验室ꎬ 北京 100012
2.同济大学环境科学与工程学院ꎬ 上海 200092
3.安徽工程大学生物与化学工程学院ꎬ 安徽 芜湖 241000

聚丙烯酰胺MSDS 安全技术说明书

聚丙烯酰胺MSDS 安全技术说明书

聚丙烯酰胺(PAM)安全技术说明书(MSDS)Polyacrylamide (PAM)Safety specifications产品名称:聚丙烯酰胺Product name: polyacrylamide产品号码:RA715identification symbol:RA63810产品用途:废水处理用絮凝剂Product use: wastewater treatment with flocculant一、化学品及厂商资料Chemicals and vendor information化学品商品名:聚丙烯酰胺或PAMChemical trade name: polyacrylamide企业名称:Company name: Beijing sea environmental protection technology co., LTDTEL:+86-010-FAX:+86-010-二、成分、组成信息Composition information化学品名称:聚丙烯酰胺Chemical name: polyacrylamide相对分子量: 1200万relative molecular weight:1200万离子性:阳离子Ion: cationic化学类别: 螯合剂型聚合物Chemical categories: chelate polymer dosage form容积密度: 0.70gms/cm3Bulk density: 0.70gms/cm3粘度:(1.0%SOL)950mPa•SViscosity:(1.0%SOL)950mPa•S外观与性状: 白色粒状固体,稀释后呈无色液体,无臭Appearance and properties: white granular solid, diluted shows colorless liquid, odourless水分(0.1%SOL):10%以下。

史锁芳治疗感染后咳嗽经验

史锁芳治疗感染后咳嗽经验

史锁芳治疗感染后咳嗽经验薛宇菲,唐艳芬,章 匀,洪玲玲(南通市中医院肺病科,江苏 南通 226000)[摘要] 史锁芳教授认为感染后咳嗽病位在肺,涉及肝脾,病理因素多责之于风、痰、火。

临床治疗可根据病程分阶段论治:初期重在宣透,处方以三拗汤加质轻性浮之品;中期以清解郁热为主,辅以疏风散邪,常用桑叶、桑白皮、薄荷等;晚期清热养阴、润肺益气,处方可选麦门冬汤、沙参麦冬汤、清燥救肺汤加减。

同时,史教授还善用“风四药”(桑叶、菊花、全蝎、僵蚕)疏风解痉止咳。

对于难治性感染后咳嗽,史教授遵循因人制宜、因时制宜原则,因势利导,常获佳效。

附验案2则。

[关键词] 感染后咳嗽;分期辨治;风药;因人制宜;因时制宜;六经欲解时;史锁芳[中图分类号] R256.11;R249 [文献标志码] A [文章编号] 0257-358X (2024)02-0185-05DOI :10.16295/ki.0257-358x.2024.02.015SHI Suofang ’s Experience in Treating Post -Infectious CoughXUE Yufei ,TANG Yanfen ,ZHANG Yun ,HONG Lingling(Department of Respiratory Medicine ,Nantong Hospital of Traditional Chinese Medicine ,Nantong 226000,China )Abstract Professoer SHI Suofang believes that post -infectious cough is located in the lungs and involvesthe liver and spleen ,with pathological factors mostly associated with the wind ,phlegm and fire. Clinical treatment can be staged according to the course of the disease. Treatments at the initial stage focus on dispersing and penetrating ,with the prescription mainly consisting of San'ao Decoction (三拗汤) and Chinese medicinals with light and floating properties. Treatments at the middle stage mainly aim at clearing stagnant heat ,supplemented by dispersing wind and dissipating pathogen ,commonly using Sangye (Mori Folium ),Sangbaipi (Mori Cortex ),Bohe (peppermint ). Treatments at the late stage focus on clearing heat and nourishing yin ,moistening the lungs and benefiting qi ,with prescriptions such as modified Maimendong Decoction (麦门冬汤),Shashen Maidong Decoction (沙参麦冬汤) and Qinzao Jiufei Decoction (清燥救肺汤). At the sametime ,Professor SHI is also skilled in using “four wind medicinals ” [Sangye ,Juhua (Chrysanthemi Flos ),Quanxie (Scorpio ),Jiangcan (Bombyx Batryticatus )] to disperse wind ,relieve spasms ,and stop cough. Forintractable post -infectious cough ,Professor SHI follows the principles of individualizing treatment accordingto the person and the timing ,often achieving good results. Two proved cases are attached.Keywords post -infectious cough ;staged differentia⁃tion and treatment ;wind medicinals ;individualized treatment ;timely treatment ;time for six -meridiandiseases to resolve ;SHI Suofang[收稿日期] 2023-04-13[基金项目] 南通市中医医疗联盟课题项目(编号:TZYK202105)[作者简介] 薛宇菲(1995—),男,江苏南通人,医学硕士,住院中医师,主要从事中医治疗肺脏病临床研究。

职业健康监护技术与诊断处理再认识(Occupational health monitoring and diagnosis treatment)

职业健康监护技术与诊断处理再认识(Occupational health monitoring and diagnosis treatment)

职业健康监护技术与诊断处理再认识(Occupational health monitoring and diagnosis treatment)Occupational health examination and occupational disease diagnosis standard and the disposition of common problems1. Who saves () B on the occupational health checklistA. laborerB. EmployerC. Inspection organizationD. Health administration2. The occupational-disease-diagnosis institutions shall organize the diagnosis (C) within the time of acceptanceA, 10 daysB, 20 daysC, 30 daysD, 40 days3. Which of the following is not the legal basis for the diagnosis of occupational diseases () BA, the law of the People's Republic of China on occupationaldiseasesB. Measures for the management of occupational health careC. National occupational health standardsD. The terminology of occupational diseases4. Which of the following does not belong to the purpose of occupational health examination () AA. Determine whether the laborer is fit to continue with the workB. Understand the health status of workers when they leave the postC. Responsibility for health damageD. determine whether workers have occupational health damage5. The purpose of pre-job occupational health examination is () DA, discover occupational taboo card, distinguish responsibilityB. Master the health status of the laborer, as the basic information of the laborer's health observationC, determine whether the laborer has a professional taboo cardand whether he can do the jobD, above all6. Before any time, the occupational health inspection body shall compile and report the occupational health examination data of this year and report to the local administrative department of health () AA, 10 OctoberB, 10 DecemberC, October 31D, December 31The following is the legal basis for occupational health examination () DA, the law of the People's Republic of China on occupational diseasesB. Measures for the management of occupational health careC. National occupational health standardsD, above allThe purpose of occupational health care is () AA. prevention of occupational diseaseB. Occupational diseaseC. To evaluate the relationship between health changes of workers and occupational-disease-inductive factorsD. Evaluation of occupational hazardNo group or department of the following shall keep the occupational health examination report () CA, employerB. The health administrative department of the employerC. laborersMedical institution10. The employer shall submit the supplementary material () C in the time when it receives the notification of supplementary materialsA, 7 daysB, 10 daysC, 15 daysD, 21 daysNew application of occupational disease diagnosis standard1. After high concentration of high concentration of benzene, which of the following tissues or sites has the highest concentration () CA, the bone marrowB. Adipose tissueC, the brainD, bloodThe main way that mercury invades the body is () AA. respiratory tractB. digestive tractC, skinD, mucous membrane3. The physicochemical properties of phenol are not described correctly (C)A, the deliquescence, slightly soluble in waterB, flammable, explosiveNo smellD, white, translucent acicular crystalsThe total phenol exposure limit is () DA, 155 mg/g creatinineB, 145 mg/g creatinineC, 135 mg/g creatinineD, 125 mg/g creatinine5. The physicochemical properties of benzene are not correctly described () BA, slightly soluble in waterB, not volatileC. Special smellD, soluble in a variety of organic solvents6. Which of the following does not belong to the three typical manifestations of mercury chronic poisoning () BA, elationB, dermatitisC, intentional tremorD. Oral inflammation7. Which organ in the body has the highest mercury content () CA, liverB, spleenC, kidneyD, lung8. Which of the following can be diagnosed as moderately phenolic poisoning () BA, dizzinessB. Moderate toxic nephropathyC, hemolysisD, shockThe main path of phenol excretion is () AA, urineB, excrement and urineC, sweatD, breathe outThe chronic toxicity of benzene is mainly manifested in () BA. central nerve anesthesiaB. Effects of bone marrow hematopoiesisC. Affect the respiratory systemD, affect the digestive systemOccupational health monitoring and evaluation1. Occupational health care content has () DA. contact controlB. Medical contactC. Information managementD, above all2. Which of the following items must be checked () AA, white blood cell count and hemoglobin quantificationBC, neurologyD, urine routine3. Patients with raynaud's disease may not engage in the following related works () CA, noiseB, high temperatureC, vibrationD, dustWhich of the following does not belong to the occupational contraindication () C of lead related worksA. neurological diseasesB. hypertensionC. skin diseaseD, liver and kidney disorders5. The quality of the medical and health institutions that canconduct occupational health examinations shall be approved by the department of health administration () BA, ministry of healthB. Provincial health administration departmentC. Municipal health administration departmentD. County health administration department6. The object of pre-employment health inspection does not include which of the following () AA.B. New video userC. Job changersD. Process changers7. Which of the following items is required to check () DA, dermatologyB, urine routineC, glycosuriaD. X-ray of the bone8. Excessive or functional uterine bleeding may not be related to the following related work () BA, arsenicB, benzeneC, mnD, mercury9. Carriers of hepatitis b can not engage in the following related works () AA, trinitrotolueneB, high temperatureC, the noiseD, vibration10. When calculating the detection rate of chronic diseases (pneumoconiosis), the person who is examined is the length of time () CA, 3 monthsB, 6 monthsC, 1 yearD, 2 yearsTechnical specification for occupational health monitoring (GBZ188 -- 2007)1. The anaemia may not be engaged in the following work () BA, the minersB battery production workshopC, flour millD, geological2. Occupational contraindication of dust industry is () DA, active tuberculosisB. Chronic obstructive pulmonary diseaseC, idiopathic pulmonary fibrosisD, above all3. When contact with coal dust is 15 years, how long should it be followedA, 5 yearsB, 8 yearsC, 10 yearsD, 15 years4. Related to mercury and its inorganic compounds, if the concentration of hazardous substances in the workplace exceeds the national health standard, the health inspection cycle is () BA, 6 months, 1 timeB, 12 monthsC, 18 monthsD, 24 months5. Which of the following situations can be considered as A check () A during departureA, the last health check during the time of duty is 3 months before departureB. The last health check during the job was six months before departureC, the last health check during the period of duty was 8 months before departureD. The last health check during the job was 10 months before departure6. It is incorrect to say (C) that the health inspection statement is incorrectA, the purpose is to find out whether there are any professional taboosB. Establish the basic health records of theoccupational-disease-inductive factorsC. For recommended occupational health examinationsD, should be done before beginning to do harmful homework7. Which of the following does not belong to the occupational contraindication of chlorine gas () DA, copdB. bronchial asthmaC, diffuse pulmonary fibrosisD, porphyrinThe target disease of occupational health monitoring is () AA, occupational disease and occupational taboosB. complicationsC. critically illD. High risk diseaseAfter two years of initial contact, how often should you check () AA, 12 monthsB, 8 monthsC, 6 monthsD, 3 months10. This technical specification has added which of the following occupational health monitoring () BA, video jobB. Prevention and control of liver inflammationC. electrical workD. pressure vessel operationDiagnosis and prevention of lead poisoning1. Which of the following conditions does not transform the phosphate lead stored in the bone into lead phosphate () AA. drink milkB, calcium deficiency,C, drinkingD. Osteoporosis2. Which of the following content of blood lead belongs to the scope of observation () AA, 2.0 mu mol/LB, 3.0 mu mol/LC, 4.0 mu mol/LD, 5.0 mu mol/L3. Which of the following can be classified as severe lead poisoning () BA, mildly toxic peripheral neuropathyB. Toxic encephalopathyC, anemia,D, angina4. The partial reduction of lead in red blood cells is () BA, 24 daysB, 25 daysC, 26 daysD, 27 daysThe absorption of lead is incorrect () BOne tenth of A and pb is absorbed after entering the digestive tractB. In the production environment, the main absorption route is the digestive tractC and tetraethyl lead can be absorbed through the skin and mucosaD. inorganic lead compounds cannot pass through intact skinWhich of the following needs to be removed from lead () CA. mild poisoningB. Moderate poisoningC. Severe poisoningD. Object of observation7. The main passage of lead in the human body is () DA, the salivaB, sweatC, urinateD, excrement and urine8. The treatment of acute lead poisoning in children has (D)。

清洁验证的法规要求

清洁验证的法规要求

CLEANING VALIDATION 清洁验证1 Cleaning validation should be performed in order to confirm the effectiveness of a cleaning procedure. The rationale for selecting limits of carry over of product residues, cleaning agents and microbial contamination should be logically based on the materials involved. The limits should be achievable and verifiable.清洁验证是为了确保清洁程序的有效性而进行的。

对于产品残留物清除、清洁剂和微生物污染的限度选择,理论上应该以相关原料为基础。

这些限度应该是可以达到的并且是可以被证实的。

2 Validated analytical methods having sensitivity to detect residues or contaminants should be used. The detection limit for each analytical method should be sufficiently sensitive to detect the established acceptable level of the residue or contaminant.应该使用经确认的、对于检测残留物或污染物具有灵敏度的分析方法。

每一种分析方法的检测限度应该足够灵敏来检测出符合可接受标准要求的残留物或污染物。

3 Normally only cleaning procedures for product contact surfaces of the equipment need to be validated. Consideration should be given to non-contact parts. The intervals between use and cleaning as well as cleaning and reuse should be validated. Cleaning intervals and methods should be determined.一般情况下,仅仅对于和产品接触的设备表面需要进行清洁验证。

USP40-NF35通用章节目录

USP40-NF35通用章节目录

USP40-NF35通用章节目录USP40-NF35通用章节目录USP40-NF35通用章节指导目录Guide to General Chapters 通用章节指导(标注底色部分为USP40-NF35新增章节)General Requirements for Test and Assays检查与含量分析的一般要求<1>INJECTIONS AND IMPLANTED DRUG PRODUCTS (PARENTERALS)—PRODUCT QUALITY TESTS 注射和植入药物产品(注射用) —产品质量测试<1>INJECTIONS注射剂<2>ORAL DRUG PRODUCTS—PRODUCT QUALITY TESTS 口服药物产品质量测试<3>TOPICAL AND TRANSDERMAL DRUG PRODUCTS—PRODUCT QUALITY TESTS局部和透皮药物产品—产品质量测试<4>MUCOSAL DRUG PRODUCTS—PRODUCT QUALITY TESTS 粘膜药物产品质量测试<5>INHALATION AND NASAL DRUG PRODUCTS—GENERAL INFORMATION AND PRODUCT QUALITY TESTS 吸入剂产品—产品质量测试<7>LABELING 标签<11>USP REFERENCE STANDARDS USP标准品Apparatus for Test and Assays用于检查与含量分析的器具<17>PRESCRIPTION CONTAINER LABELING处方容器标签<21>THERMOMETERS温度计(本版本已删除)<31>VOLUMETRIC APPARATUS容量器具<41>BALANCES天平Microbiological Tests 微生物检查法<51>ANTIMICROBIAL EFFECTIVENESS TESTING抗菌剂有效性检查法<55>BIOLOGICAL INDICATORS—RESISTANCE PERFORMANCE TESTS生物指示剂-耐药性实验<61>MICROBIOLOGICAL EXAMINATION OF NONSTERILE PRODUCTS: MICROBIAL ENUMERATION TESTS非无菌产品的微生物限度检查:微生物列举检查法<62>MICROBIOLOGICAL EXAMINATION OF NONSTERILE PRODUCTS: TESTS FOR SPECIFIED MICROORGANISMS 非无菌产品的微生物限度检查:特定微生物检查法<63>MYCOPLASMA TESTS 支原体检查法<71>STERILITY TESTS无菌检查法Biological tests and assays生物检查法与测定法<81>ANTIBIOTICS—MICROBIAL ASSAYS抗生素-微生物测定<85>BACTERIAL ENDOTOXINS TEST细菌内毒素检查法<87>BIOLOGICAL REACTIVITY TESTS, IN VITRO体外的生物反应性检查法<88>BIOLOGICAL REACTIVITY TESTS, IN VIVO 体内的生物反应性检查法<89>ENZYMES USED AS ANCILLARY MATERIALS IN PHARMACEUTICAL MANUFACTURING药品生产中酶作为辅料所使用<89.1>COLLAGENASEⅠ胶原酶Ⅰ<89.2>COLLAGENASEⅡ胶原酶Ⅱ<90>FETAL BOVINE SERUM—QUALITY ATTRIBUTES AND FUNCTIONALITY TESTS牛胎儿血清-质量品质和功能检查法<91>CALCIUM PANTOTHENATE ASSAY泛酸钙测定法<92>GROWTH FACTORS AND CYTOKINES USED IN CELL THERAPY MANUFACTURING在细胞疗法中使用生长因子和细胞因子<111>DESIGN AND ANALYSIS OF BIOLOGICALASSAYS 生物测定法的设计与分析<115>DEXPANTHENOL ASSAY右泛醇(拟胆碱药)测定法<121>INSULIN ASSAYS胰岛素测定法<121.1>PHYSICOCHEMICAL ANALYTICAL PROCEDURES FOR INSULINS胰岛素的物理化学分析程序<123>GLUCAGON BIOIDENTITY TESTS 高血糖素的生物鉴别检查法<124>ERYTHROPOIETIN BIOASSAYS 红细胞生成素的微生物测定<126>SOMATROPIN BIOIDENTITY TESTS 生长激素的生物鉴别检查法<127>FLOW CYTOMETRIC ENUMERATION OF CD34+ CELL 流式细胞术计术34阳性细胞<129>ANALYTICAL PROCEDURES FOR RECOMBINANT THERAPEUTIC MONOCLONAL ANTIBODIES重组治疗性单克隆抗体的分析方法<130>PROTEIN A QUALITY ATTRIBUTES 蛋白质A的质量特征<151>PYROGEN TEST热原检查法<161>TRANSFUSION AND INFUSIONASSEMBLIES AND SIMILAR MEDICAL DEVICES 输血输液用具以及相类似的医疗器械<162>DIPHTHERIA ANTITOXIN POTENCY TESTING FOR HUMAN IMMUNE GLOBULINS 人免疫球蛋白的白喉抗毒素效力检测<165>PREKALLIKREIN ACTIV ATOR前激肽释放酶原激活剂<171>VITAMIN B12 ACTIVITY ASSAY……2548维生素B12活性测定法Chemical Tests and assays化学实验检查与测定法鉴别检查<181>IDENTIFICATION—ORGANIC NITROGENOUS BASES鉴别-有机氮碱化合物<191>IDENTIFICATION TESTS—GENERAL鉴别实验-通用<193>IDENTIFICATION—TETRACYCLINES鉴别-四环素类<197>SPECTROPHOTOMETRIC IDENTIFICATION TESTS分光光度计鉴别实验<201>THIN-LAYER CHROMATOGRAPHIC IDENTIFICATION TEST薄层色谱鉴别实验<202>IDENTIFICATION OF FIXED OILS BYTHIN-LAYER CHROMATOGRAPHY 薄层色谱法对非挥发性油的鉴别<203>HIGH-PERFORMANCE THIN-LAYER CHROMATOGRAPHY PROCEDURE FOR IDENTIFICATION OF ARTICLES OF BOTANICAL ORIGIN 高性能薄层色谱法对植物的鉴别Limit Tests 限度检查法<206>ALUMINUM铝<207>TEST FOR 1,6-ANHYDRO DERIV ATIVE FOR ENOXAPARIN SODIUM依诺肝素钠的酐类衍生物实验<208>ANTI-FACTOR Xa AND ANTI-FACTOR IIa ASSAYS FOR UNFRACTIONATED AND LOW MOLECULAR WEIGHT HEPARINS普通肝素和低分子肝素产品中抗体Xa和抗体IIa测定<209>LOW MOLECULAR WEIGHT HEPARIN MOLECULAR WEIGHT DETERMINATIONS低分子肝素钠分子量测定<211>ARSENIC砷<212>OLIGOSACCHARIDE ANALYSIS 低聚糖的分析<221>CHLORIDE AND SULFATE氯和硫<223>DIMETHYLANILINE二甲基苯胺<226>4-EPIANHYDRO-TETRACYCLINE4-?-四环素<227>4-AMINOPHENOL IN ACETAMINOPHEN-CONTAINING DRUG PRODUCTS对乙酰氨酚药物产品中氨基酚<228>ETHYLENE OXIDE AND DIOXANE 环氧乙烷和二氧六环<231>HEA VY METALS重金属(删除)<232>ELEMENTAL IMPURITIES—LIMITS 元素杂质-限度<233>ELEMENTAL IMPURITIES—PROCEDURES 元素杂质-规程<241>IRON铁<251>LEAD铅<261>MERCURY汞<267>POROSIMETRY BY MERCURY INTRUSION 水银孔隙仪<268>POROSITY BY NITROGEN ADSORPTION–DESORPTION 氮吸附-解吸测定孔隙率<271>READILY CARBONIZABLE SUBSTANCES TEST易碳化物检查法<281>RESIDUE ON IGNITION炽灼残渣<291>SELENIUM硒Other Tests and Assays 其它检查法与测定法<301>ACID-NEUTRALIZING CAPACITY酸中和容量<311>ALGINATES ASSAY藻酸盐测定法<341>ANTIMICROBIAL AGENTS—CONTENT 抗菌剂-含量<345>Assay for Citric Acid/Citrate and Phosphate 柠檬酸/柠檬酸盐和磷酸盐的测定<351>ASSAY FOR STEROIDS类固醇(甾类化合物)测定法<361> BARBITURATE ASSAY 巴比妥类药物测定法(本版本已删除)<371>COBALAMIN RADIOTRACER ASSAY钴铵素放射性跟踪剂测定法<381>ELASTOMERIC CLOSURES FOR INJECTIONS 注射剂的弹性密封件<391>EPINEPHRINE ASSAY肾上腺素测定法<401>FATS AND FIXED OILS脂肪与混合油<411>FOLIC ACID ASSAY叶酸测定法<413>IMPURITIES TESTING IN MEDICAL GASES 医用气体杂质检查<415>MEDICAL GASES ASSAY 医用气体含量检查<425>IODOMETRIC ASSAY—ANTIBIOTICS碘量检查法-抗生素<429>LIGHT DIFFRACTION MEASUREMENT OF PARTICLE SIZE粒径的光衍射测量法<431>METHOXY DETERMINATION甲氧基测定法<441>NIACIN OR NIACINAMIDE ASSAY 烟酰或烟酰胺测定法<451>NITRITE TITRATION亚硝酸盐滴定<461>NITROGEN DETERMINATION氮测定法<466>ORDINARY IMPURITIES一般杂质<467>RESIDUAL SOLVENTS残留溶剂<469>ETHYLENE GLYCOL, DIETHYLENE GLYCOL, AND TRIETHYLENE GLYCOLIN ETHOXYLATED SUBSTANCES乙氧基物质中乙二醇、二甘醇、三甘醇测定<471>OXYGEN FLASK COMBUSTION氧瓶燃烧法<481>RIBOFLA VIN ASSAY核黄素(维生素B2)测定法<501>SALTS OF ORGANIC NITROGENOUS BASES有机氮盐<503>ACETIC ACID IN PEPTIDES 多肽类中乙酸测定<503.1>TRIFLUOROACETIC ACID(TFA)IN PEPTIDES 肽中三氟乙酸<507>PROTEIN DETERMINATION PROCEDURES 蛋白质测定程序<511>SINGLE-STEROID ASSAY单一的类固醇测定法<525>SULFUR DIOXIDE 二氧化硫<531>THIAMINE ASSAY硫胺素测定法<541>TITRIMETRY滴定法<551>VITAMIN E ASSAY维生素E测定法<561>ARTICLES OF BOTANICAL ORIGIN植物起源的药品<563>IDENTIFICATION OF ARTICLES OF BOTANICAL ORIGIN植物药品的鉴别<565>BOTANICAL EXTRACTS植物提取<571>VITAMIN A ASSAY维生素A测定法<580>VITAMIN C ASSAY 维生素C的测定法<581>VITAMIN D ASSAY维生素D测定法<591>ZINC DETERMINATION锌的测定法Physical Test and Determinations物理检查与测定法<601>INHALATION AND NASAL DRUG PRODUCTS: AEROSOLS, SPRAYS, ANDPOWDERS—PERFORMANCE QUALITYTESTS吸入剂、鼻雾剂:气溶胶,喷雾,干粉-质量通则<602>PROPELLANTS 推进剂<603>TOPICAL AEROSOLS 局部喷雾剂<604>LEAK RATE 渗漏率<610>ALTERNATIVE MICROBIOLOGICAL SAMPLING METHODS FOR NONSTERILEINHALED AND NASAL PRODUCTS非无菌吸入和鼻雾剂可供选择的微生物取样方法<611>ALCOHOL DETERMINATION乙醇测定法<616>BULK DENSITY AND TAPPED DENSITY堆密度与振实密度<621>CHROMATOGRAPHY色谱法<631>COLOR AND ACHROMICITY呈色与消色<641>COMPLETENESS OF SOLUTION溶解度<643>TOTAL ORGANIC CARBON总有机碳<645>WATER CONDUCTIVITY水电导率<651>CONGEALING TEMPERATURE凝点温度<659>PACKAGING AND STORAGE REQUIREMENTS 包装和储藏要求<660>CONTAINERS—GLASS 容器-玻璃<661>CONTAINERS—PLASTICS容器-塑料<661.1>PLASTIC MATERIALS OF CONSTRUCTION塑料包装材料<661.2>PLASTIC PACKAGING SYSTEMS FOR PHARMACEUTICAL USE药用塑料包装系统<670>AUXILIARY PACKAGING COMPONENTS 辅助包装部件<671>CONTAINERS—PERFORMANCE TESTING 容器-性能测试<691>COTTON棉花<695>CRYSTALLINITY结晶度<696>CHARACTERIZATION OF CRYSTALLINE SOLIDS BY MICROCALORIMETRY AND SOLUTION CALORIMETRY 通过溶液量热学测定结晶性<697>CONTAINER CONTENT FOR INJECTIONS 注射剂容器容积<698>DELIVERABLE VOLUME抽取体积<699>DENSITY OF SOLIDS固体密度<701>DISINTEGRATION崩解时限<705>QUALITY ATTRIBUTES OF TABLETS LABELED AS HA VING A FUNCTIONAL SCORE ?<711>DISSOLUTION 溶出度<721>DISTILLING RANGE馏程<724>DRUG RELEASE药物释放度<729>GLOBULE SIZE DISTRIBUTION IN LIPID INJECTABLE EMULSIONS脂类可注射的乳剂的粒径分布<730>Plasma Spectrochemistry 血浆光谱化学?<731>LOSS ON DRYING4干燥失重<733>LOSS ON IGNITION灼烧失重<735>X-RAY FLUORESCENCE SPECTROMETRY X射线光谱<736>MASS SPECTROMETRY 质谱<741>MELTING RANGE OR TEMPERATURE熔距或熔点<751>METAL PARTICLES IN OPHTHALMIC OINTMENTS眼用软膏中的金属粒子<755>MINIMUM FILL最低装量<761>NUCLEAR MAGNETIC RESONANCE核磁共振<771>OPHTHALMIC OINTMENTS眼用软膏<776>OPTICAL MICROSCOPY光学显微镜<781>OPTICAL ROTATION旋光度<782>VIBRATIONAL CIRCULAR DICHROISM SPECTROSCOPY 振动圆二色谱<785>OSMOLALITY AND OSMOLARITY渗透压<786>PARTICLE SIZE DISTRIBUTION ESTIMATION BY ANALYTICAL SIEVING筛分法估算粒径分布<787>SUBVISIBLE PARTICULATE MATTER IN THERAPEUTIC PROTEIN INJECTIONS显微计数法在治疗性蛋白注射剂中应用<788>PARTICULATE MATTER IN INJECTIONS 注射剂中的不溶性微粒<789>PARTICULATE MATTER IN OPHTHALMIC SOLUTIONS眼用溶液中的不溶性微粒<790>VISIBLE PARTICULATES IN INJECTIONS 注射剂中可见异物<791>pH<795>PHARMACEUTICAL COMPOUNDING—NONSTERILE PREPARATIONS 药物混合-非无菌制剂<797>PHARMACEUTICAL COMPOUNDING—STERILE PREPARATIONS药物混合-无菌制剂<800>HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS 在医疗环境中危险药品的处理<801>POLAROGRAPHY极谱法<811>POWDER FINENESS粉剂细度<821>RADIOACTIVITY放射性<823>POSITRON EMISSION TOMOGRAPHY DRUGS FOR COMPOUNDING,INVESTIGATIONAL, AND RESEARCHUSES用于正电子发射断层造影术的放射性药物<831>REFRACTIVE INDEX折光率<841>SPECIFIC GRA VITY比重<846>SPECIFIC SURFACE AREA 比表面积<851>SPECTROPHOTOMETRY AND LIGHT-SCATTERING分光光度计与光散射(本版本已删除)<852>ATOMIC ABSORPTION SPECTROSCOPY 原子吸收光谱<853>FLUORESCENCE SPECTROSCOPY 荧光光谱<854>MID-INFRARED SPECTROSCOPY 中红外光谱<855>NEPHELOMETRY, TURBIDIMETRY, AND VISUAL COMPARISO浊度测定、比浊法、视觉比较<857>ULTRA VIOLET-VISIBLE SPECTROSCOPY 紫外可见光谱<861>SUTURES—DIAMETER缝线-直径?<871>SUTURES—NEEDLE ATTACHMENT缝线-穿孔实验<881>TENSILE STRENGTH张力<891>THERMAL ANALYSIS热分析<905>UNIFORMITY OF DOSAGE UNITS制剂单位的含量均匀度<911>VISCOSITY—CAPILLARY METHODS黏度-毛细管法<912>VISCOSITY—ROTATIONAL METHODS 黏度-旋转法<913>VISCOSITY—ROLLING BALL METHOD 黏度-球法<914>VISCOSITY—PRESSURE DRIVEN METHODS 黏度-压力驱动方法<921>WATER DETERMINATION水分测定<941>CHARACTERIZATION OF CRYSTALLINE AND PARTIALLY CRYSTALLINE SOLIDSBY X-RAY POWDER DIFFRACTION (XRPD)X光衍射General Information通用信息<1004>MUCOSAL DRUG PRODUCTS—PERFORMANCE TESTS粘膜药物产品性能测试<1005>ACOUSTIC EMISSION 声频发射<1010>ANALYTICAL DATA—INTERPRETATIONAND TREATMENT分析数据-解释与处理<1015>AUTOMATED RADIOCHEMICAL SYNTHESIS APPARATUS放射性自动合成装置<1024>BOVINE SERUM 牛血清<1025>PANCREATIN胰液素<1027>FLOW CYTOMETRY 流式细胞仪<1029>GOOD DOCUMENTATION GUIDELINES 好的文件指南<1030>BIOLOGICAL ASSAY CHAPTERS—OVERVIEW AND GLOSSARY生物测定章节-综述和术语<1031>THE BIOCOMPATIBILITY OF MATERIALS USED IN DRUGCONTAINERS, MEDICAL DEVICES, ANDIMPLANTS用于药物容器、医疗设施和植入剂的材料的生物相容性<1032>DESIGN AND DEVELOPMENT OF BIOLOGICAL ASSAYS 生物试验的设计和开发<1033>BIOLOGICAL ASSAY V ALIDATION 生物试验的验证<1034>ANALYSIS OF BIOLOGICAL ASSAYS 生物测定分析<1035>BIOLOGICAL INDICATORS FOR STERILIZATION灭菌用生物指示剂(本版本已删除)<1039>CHEMOMETRICS 化学<1041>BIOLOGICS生物制剂<1043>Ancillary Material for Cell, Gene, and Tissue-Engineered Products细胞,基因与组织设计产品的辅助材料<1044>CRYOPRESERV ATION OF CELLS 细胞低温保存<1045>BIOTECHNOLOGY-DERIVED ARTICLES 生物技术提取产品(本版本已删除)<1046>CELLULAR AND TISSUE-BASED PRODUCTS细胞与组织产品<1047>GENE THERAPY PRODUCTS 基因治疗产品<1048>QUALITY OF BIOTECHNOLOGICAL PRODUCTS: ANALYSIS OF THE EXPRESSION CONSTRUCT IN CELLS USED FOR PRODUCTION OF r-DNA DERIVED PROTEINPRODUCTS生物技术产品的质量:从蛋白质产品中提取的r-DNA 产品在细胞中表达结构的分析<1049>QUALITY OF BIOTECHNOLOGICAL PRODUCTS: STABILITY TESTING OFBIOTECHNOLOGICAL/BIOLOGICALPRODUCTS生物技术产品的质量:生物技术/生物产品的稳定性实验<1050>VIRAL SAFETY EV ALUATION OF BIOTECHNOLOGY PRODUCTS DERIVEDFROM CELL LINES OF HUMAN OR ANIMALORIGIN从人或动物细胞中提取的生物技术产品的病毒安全性评估<1050.1>DESIGN, EV ALUATION,AND CHARACTERIZATION OF VIRAL CLEARANCE PROCEDURES 病毒清除过程的设计、评估和鉴定。

无磷脱脂粉 MSDS-中英文

无磷脱脂粉 MSDS-中英文

脱脂剂安全技术说明书(中英文)根据GB16483---2000编写产品型码:产品名称:无磷脱脂剂印刷日期:2019年10月8日修改于:2023年10月08日MATERIAL SAFTEY DATA SHEETCompiled according to GB16483-2000.Product Product Name: Defatted Powder Printed Date:8th,Oct.2019 Revised: 8th,Oct.2023第一部分化学品及企业标识化学品中文名称:无磷脱脂剂化学品英文名称:DEGREASING AGENT企业名称:地址:传真号码:企业应急电话:技术说明书编码:生效日期:国家应急:SECTION 1: CHEMICAL PRODUCT AND COMPANY IDENTIFICATION Chemical Chinese Name: Defatted PowderChemical English Name: Defatted PowderManufacture’s Name:Address: Zip Code: 201512Fax: Enterprise Emergency Tel:Technical specification code: Effective date :Country Emergency :第二部分成分组成信息纯品□混合物■化学品名称:无磷脱脂剂有害物成分:无浓度:粉体CAS 含量硅酸钠(98%): 1344-09-8 70% - 80%碳酸钠: 497 - 19 - 8 10% - 20% SECTION 2: COMPOSITION INFOMATION ON INGREDIENTSPure Product□Mixture■Chemical Name: Defatted PowderHarmful Composition: No Concentration: PowderCAS ContentSodium Silicate(98%): 1344-09-8 70% — 80%Sodium Carbonate:497-19-8 10% — 20%第三部分危险性概述危险性类别:强碱性化学物质侵入途径:碱性腐蚀健康危害:对人体无害,直接接触对皮肤有轻微粗糙反应环境危害:碱化燃爆危险:本品不燃,具腐蚀性、刺激性,可致人体灼伤SECTION 3: HAZARDS SUMMARIZEClassification of Hazards: Strong Alkaline ChemicalsRoutes of Invasion: Alkaline CorrosionHealth Hazards: Harmless to body, a slightly rough skin reaction if directly contacting Environment Hazards: AlkalizationFire and explosion hazards: N on-flammable, with corrosive, irritant, causing burns to human body第四部分急救措施皮肤接触:用水清洗眼睛接触:以大量的水冲洗被接触的眼睛,同时联系医院.没有医生的许可不要施任何药物于患者的眼睛。

基于亚临界技术的铬革屑水解工艺研究

基于亚临界技术的铬革屑水解工艺研究

doi:10.19677/j.issn.1004-7964.2024.03.010基于亚临界技术的铬革屑水解工艺研究张晓伟1,2,卢欣雨1,2,刘彦1.2*(1.四川大学皮革化学与工程教育部重点实验室,四川成都610065;2.四川大学轻工科学与工程学院,四川成都610065)摘要:通过单因素实验和正交试验优化,亚临界水解铬革屑最优工艺为:温度150℃、液比25、反应时间75min、CaO用量6%。

铬革屑水解率为(83.98±0.16)%。

水解过程无废液产生,水解产物主要为多肽、短肽和少量氨基酸。

水解产物的铬含量为(34.81±2.29)mg/kg,符合农业部有机肥铬含量标准,具有作为有机肥的应用前景。

铬革屑水解产生的铬绝大部分沉积在铬渣中。

铬渣浸出液的铬和六价铬含量分别为14.285mg/L 和1.544mg/L,低于国家标准《危险废物鉴别标准浸出毒性鉴别》的限值,实现了铬革屑无害化处理。

关键词:亚临界水;铬革屑;水解;铬渣;浸出毒性中图分类号:X 794文献标志码:AHydrolysis Process of Chrome Shavings based onSubcritical Technology(1.Key Laboratory of Leather Chemistry and Engineeringof Ministry of Education,Sichuan University,Chengdu 610065,China;2.College of Biomass Science and Engineering,Sichuan University,Chengdu 610065,China)Abstract:The hydrolysis of chromium shavings with subcritical water was studied by single factor experiments and optimized by orthogonal test.The optimized parameters were temperature of 150℃,liquid ratio of 25,reaction time of 75min,and calcium oxide dosage of 6%.Under these conditions,the hydrolysis ratio of chromium shavings was (83.98±0.16)%,and the chromium content of the hydrolysate was (34.81±2.29)mg/kg,which was lower than that of the organic fertilizer standard of the agriculture department.The main components of the hydrolysate were peptides and short peptide as well as a small amount of amino acids.The results indicated that the hexavalent chromium content of the hydrolysate and the solid residue were 1.317mg/kg and 30.882mg/kg,respectively,which means most of the chromium (trivalent and hexavalent)mainly exists in the solid residue.The leaching chromium content and the hexavalent chromium content in the solid residue were 14.285mg/L and 1.544mg/L,respectively,which were lower than the standard limits of “identification standard for hazardous wastes-identification for extraction toxicity ”.These results indicate that subcritical water hydrolysis for chrome shavings is a really harmless treatment and resource utilization.Key words:subcritical water;chromium shavings;hydrolysis;solid residue;leaching to xicity收稿日期:2023-10-02修回日期:2024-02-15接受日期:2024-02-22基金项目:四川省科技计划重点研发项目(2022YFS0463)第一作者简介:张晓伟(1998-),男,硕士研究生,主要研究方向:皮革固体废弃物资源化利用。

中医药名词英文翻译05(中医治法学)

中医药名词英文翻译05(中医治法学)

05.001治则principle of treatment对临床的具体立法、处方、用药等具有普遍的指导意义,在治疗疾病时必须遵循的基本原则。

05.002治病求本treatment aiming at itsroot causes针对产生疾病的根本原因进行治疗的原则。

05.003急则治标symptomatic treatment inacute condition 与缓则治本相对而言,在大出血、暴泻、剧痛等标症甚急的情况下,及时救治标病,如止血、止泻、止痛等,然后治其本病的治疗原则。

05.004缓则治本radical treatment inchronic case 与急则治标相对而言,在病势缓和、病情缓慢的情况下,针对本病的病机治疗或采取调理、补益为主的治疗原则。

05.005标本兼治treating bothmanifestation and rootcause of disease 针对病证出现的标本并重的情况,采用治标与治本相结合的治疗原则。

05.006治未病preventive treatment ofdisease 采取一定的措施防止疾病产生和发展的治疗原则,包括未病先防和既病防变两个方面。

05.007同病异治treating same diseasewith different methods 表现相同的疾病,可因人、因时、因地的不同,或由于病情的发展、病机的变化、正邪的消长等差异,采取不同治法的治疗原则。

05.008异病同治treating differentdiseases with samemethod 表现不同的疾病,由于发病机理相同,采取相同治法的治疗原则。

05.009因时制宜treatment in accordancewith seasonal conditions 考虑到时令气候寒热燥湿的不同而选择适宜的治法、方药的治疗原则。

05.010因地制宜treatment in accordancewith local conditions 考虑到地域环境的不同而选择适宜的治法、方药的治疗原则。

清洁验证指南

清洁验证指南
DECEMBER 2008
CLEANING VALIDATION
CLEANING VALIDATION
DECEMBER 2008
1. PRINCIPLE
1.1 Pharmaceutical products and active pharmaceutical ingredients (APIs) can be contaminated by other pharmaceutical products or APIs, by cleaning agents, by micro-organisms or by other material (e.g. air-borne particles, dust, lubricants, raw materials, intermediates, auxiliaries). In many cases, the same equipment may be used for processing different products. To avoid contamination of the following pharmaceutical product, adequate cleaning procedures are essential.
2. PURPOSE AND SCOPE
2.1 These guidance notes describe the validation of cleaning procedures for the removal of contaminants associated with the previous products, residues of cleaning agents as well as the control of potential microbial contaminants.

艾司西酞普兰、帕罗西汀治疗老年性抑郁症疗效比较

艾司西酞普兰、帕罗西汀治疗老年性抑郁症疗效比较

艾司西酞普兰、帕罗西汀治疗老年性抑郁症疗效比较发表时间:2017-08-25T15:45:22.380Z 来源:《航空军医》2017年第13期作者:李来德[导读] 实验组患者治疗效果明显优于对照组。

结果显示,艾司西酞普兰治疗老年性抑郁疗效更好。

(湖南省道县中医院湖南道县 425300)摘要:目的探究艾司西酞普兰、帕罗西汀治疗老年性抑郁症的疗效。

方法我院选取了时间段从2015年8月到2016年5月的84例老年性抑郁症患者,将患者随机分为两组,每组42例。

对照组服用帕罗西汀治疗;实验组患者服用艾司西酞普兰进行治疗。

使用HAMA量表和HAMD量表测定患者治疗前后的HAMA和HAMD数值。

观察对比患者治疗前后的焦虑抑郁情况以及治疗效果。

结果治疗后,实验组患者治疗效果,患者的焦虑抑郁情况明显优于对照组,差异显著(P<0.05)。

结论实验组患者治疗效果明显优于对照组。

结果显示,艾司西酞普兰治疗老年性抑郁疗效更好,安全性更高,值得临床上推广应用。

关键词:艾司西酞普兰;帕罗西汀;老年性抑郁症;疗效比较Comparison of Ai Sciplan and Pa Rossi Dean in the treatment of senile depressionLi Laide(Daoxian Hospital of Traditional Chinese Medicine of Hunan Province,Hunan Daoxian 425300)[Abstract]Objective:To investigate the efficacy of escitalopram and Pa Rossi Dean in the treatment of senile depression. Methods:our hospital selected 84 cases of elderly patients with depression from August 2015 to May 2016. The patients were randomly divided into two groups,42 cases in each group. The control group was treated with Pa Rossi Dean,and the experimental group was treated with escitalopram. The HAMA and HAMD values were measured before and after treatment using the HAMA scale and the HAMD scale. The anxiety and depression of the patients before and after treatment and the effect of treatment were observed and compared. Results:after treatment,the treatment effect,anxiety and depression of the experimental group were better than the control group,the difference was significant(P < 0.05). Conclusion:the treatment effect of the experimental group is better than the control group. The results show that Ai Sciplan is better and safer in the treatment of senile depression,and is worthy of clinical application. [Keywords]escitalopram;paroxetine;senile depression;curative effect comparison;老年性抑郁症是临床上较为常见的心理疾病,近些年呈现高发的趋势[1]。

北大考研-环境科学与工程学院研究生导师简介-叶正芳

北大考研-环境科学与工程学院研究生导师简介-叶正芳

爱考机构 中国高端考研第一品牌(保过 保录 限额)
2010.1-2010.12 南水北调东线治污新理念与成效研究 国务院南水北调办 项目负责人 25
2009.10-2010.9. 垃圾渗滤液处理的组合技术及工艺开发 北京市 项目负责人 15
2008.1-2012.12 功能化载体的研究与试制 企业委托 项目负责人 50
研究领域
污水处理、地下水处理、固定化微生物(酶)、功能材料等相关的科学与技术研究 奖励荣誉
全部获奖人员排名 获奖时间 获奖项目类别(国家、省部、校) 奖励名称 等级
倪晋仁,叶正芳,崔锋,王志民,籍国东等 16 人
2007
爱考机构 中国高端考研第一品牌(保过 保录 限额)
2011.6-2012.12 B 市重金属污染土壤修复示范工程项目 B市 项目负责人 75
2011.9-2012.12 B 市重金属污染土壤背景值监测与评估项目 B市 项目负责人 640
2011.9-2012.12 B 市重金属污染整治与生态修复系统规划 B市 项目负责人 290
2007.10-2008.9 微污染水体净化关键材料和装置开发 北京市 项目负责人 15
高等学校科学技术进步奖 固定化微生物处理高氨氮废水的研究 一等
叶正芳,倪晋仁 2008 北京市发明专利奖 一种制备聚氨酯及生物固定化载体的工艺 二等
王刚,邱熔处,叶正芳,周程,邢秀兰等 9 人 2010 甘肃省/兰州市科学技术进步奖 H—BAF 综合技术用于污水再生利用工程 二等/一等
叶正芳 2006 甘肃省十大优秀专利奖 曝气生物流化池 十大优秀专利
代表性论文
爱考机构 中国高端考研第一品牌(保过 保录 限额)
1.Peer-reviewedJournalPublications(47intotal)

Airnov新身份、新愿景、新追求

Airnov新身份、新愿景、新追求

Study on the Physicochemical Properties of HazardousWaste Incinerator Slag and Fly Ash and Thinkingabout the CompatibilityZHANG Jianping MA CuicuiAbstract:Through a series of detection and analysis of hazardous waste incinerator slag and fly ash,the location andcontent of hazardous elements in hazardous waste deposited in the incineration line was understood,and the main chemical form of their existence were inferred,so as to provide certain ideas for future hazardous waste compatibility work.Key words:Hazardous waste;Incineration;Fly ash;Slag险废物焚烧配伍有助于危险废物焚烧工况的稳定,有利于延长耐火材料的寿命和焚烧设施的使用周期,从而可降低运营成本。

在实际的焚烧处置过程中,理想的危险废物焚烧配伍是希望有害元素以稳定态的形式富集在炉渣处,而不进入烟道。

因此,在前端进行物料配伍时应该注意以下几点:(1)对于较易挥发的元素、化学物质和重金属元素,可考虑添加辅材的方法。

利用辅材的分子结构特点或晶格缺陷等使其附着或镶嵌在辅材中,从而提高其熔点温度,随辅材一起进入炉渣中。

(2)充分利用三元、四元相图的理论基础,结合物料的实际化学组成并选择合适的与之相配的废料,尽量使其形成共熔物。

危险废物处理处置工程环境防护距离技术规范

危险废物处理处置工程环境防护距离技术规范

危险废物处理处置工程环境防护距离技术规范1适用范围本标准规定了危险废物处理处置工程和专业集中贮存场所,与敏感目标及地表水体之间所需的环境防护距离。

本标准适用于上海市危险废物处理处置工程和专业集中贮存场所的环境管理。

2规范性引用文件下列文件中的条款通过本标准引用而成为本标准的条款。

凡是未注明日期的引用文件,其有效版本适用于本标准。

(1)《国家危险废物名录》(环境保护部令第1号)(2)《危险废物贮存污染控制标准》GB18597(3)《危险废物焚烧污染控制标准》GB18484(4)《危险废物填埋污染控制标准》GB185983术语和定义下列术语和定义适用于本文件3.1危险废物Hazardous Wastes指列入国家危险废物名录或者根据国家规定的危险废物鉴别标准和鉴别方法认定的具有危险性的废弃物。

3.2填埋Landfill指将危险废物最终置于符合环境保护规定要求的填埋场的活动。

填埋场是处置废物的一种陆地处置设施,它由若干个处置单元和构筑物组成,处置场有界限规定,主要包括废物预处理设施、废物填埋设施和渗滤液收集处理设施。

3.3焚烧Incineration指焚化燃烧危险废物使之分解并无害化的过程。

3.4物化处理Physicochemical Treatment指系统运用物理和/或化学的方法使危险废物资源化、稳定化和无害化的过程。

3.5集中贮存场所Centralized Storage Plant指区域性危险废物专业化集中收集并贮存的场所。

3.6环境防护距离Environment Protection Zone产生有害因素的部门(危险废物生产车间或装置、未经稳定化处理的危险废物集中贮存设施)边界至居民区、学校、医院等敏感目标边界及地表水体的最小距离。

3.7地表水Surface Water指长江,市管河道、区(县)管河道、镇(乡)管河道、湖泊、以及本市区县政府和环保主管部门认定的其他需要保护的天然水体。

4指标要求4.1自颁布之日起,新建、改建、扩建危险废物处理处置工程和专业集中贮存场所应执行表1环境防护距离限值要求。

土壌汚染浄化ppt

土壌汚染浄化ppt
Measure
In-situ insolubilization Heavy metals
<2nd Std.* >2nd Std.
VOCs
<2nd Std. >2nd Std.
Agricultural chemicals, etc
<2nd Std. >2nd Std.
○ ○ ○ ○ ○
× △ △ ○ ○
× ○ ○ × ○
× × × × ○
× ○ ○ ○ ○
× × × ○ ○
In-situ shuttingin
Shutting-in with water barrier
Cutting off
Evacuation and In-situ remediation
* 2nd Std. : Secondary elution standard
(Dioxins, PCBs, Agricultural chemicals…)
Soil elution standard and soil content standard under the Soil Pollution Control Law
Controlled substance Dichloromethane Carbon tetrachloride 1,2-Dichloromethane 1,1-Dichloroethylene cis-1,2-Dichloroethylene 1,1,1-Trichloroethane 1,1,2Trichloroethane Trichloroethylene Tetrachloroethylene Benzene 1,3-Dichloropropene Cadmium Lead Hexavalent chromium Arsenic Total mercury Alkyl mercury Selenium Fluorine Boron Cyanogen PCB Thiuram Simazine Thiobencarb Organic phosphorus Soil elution standard (mg/L) 0.02 0.002 0.004 0.02 0.04 1 0.006 0.03 0.01 0.01 0.002 0.01 0.01 0.05 0.01 0.0005 Not to be detected 0.01 0.8 1 Not to be detected Not to be detected 0.006 0.003 0.02 Not to be detected Secondary elution standard (mg/L) 0.2 0.02 0.04 0.2 0.4 3 0.06 0.3 0.1 0.1 0.02 0.3 0.3 1.5 0.3 0.005 Not to be detected 0.3 24 30 1 0.003 0.06 0.03 0.2 1 Soil content standard (mg/kg) - - - - - - - - - - - 150 150 250 150 15 - 150 4,000 4,000 50 (free cyanide) - - - - - Classification

美国医师协会压疮指南

美国医师协会压疮指南

Pressure Ulcers CPG Assessment压疮评估
Pressure Ulcer Classifications – continued • Stage 3: Full thickness skin loss involving damage to, or
necrosis of, subcutaneous tissue that may extend down to, but not through, fascia. The ulcer presents clinically as a deep crater with or without undermining of adjacent tissue 三期压疮 • Stage 4: Full thickness skin loss with extensive destruction, tissue necrosis or damage to muscle, bone, or supporting structures (e.g., tendon, joint capsule). Undermining and sinus tracts also may be associated四 期压疮
An effective assessment includes有效的评估包括:
• Define and interpret factors affecting treatment and wound healing such as physical, functional and psychosocial factors定义和解释关于治疗和伤口康复的影 响因素,例如身体的,功能的和心理方面的因素。
• Shearing剪切力 • Friction摩擦力 • Moisture潮湿
相关主题
  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。

2003055435
This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use. Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage or retrieval system, without prior permission in writing from the publisher. The consent of CRC Press LLC does not extend to copying for general distribution, for promotion, for creating new works, or for resale. Specific permission must be obtained in writing from CRC Press LLC for such copying. Direct all inquiries to CRC Press LLC, 2000 N.W. Corporate Blvd., Boca Raton, Florida 33431. Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation, without intent to infringe.
Tang, Walter Z. Physicochewastes / Walter Z. Tang p. cm. Includes bibliographical references and index. ISBN 1-56676-927-2 (alk. paper) 1. Hazardous wastes—Purification. I. Title. TD1060.T35 2003 628.4′2—dc21
Preface
On average, one ton of hazardous waste per person is generated annually by industries in the United States. Before the Resource Conservation and Recovery Act of 1984, hazardous wastes were improperly disposed of into the environment without any regulation. As a result, remediation of these contaminated sites and management of the ongoing hazardous waste sources are two major tasks to be achieved by treatment technologies. Due to the complex nature of the contaminated media and of the pollutants, environmental professionals are facing a host of questions, such as: What are the contaminated media? What is the nature of the pollutants? What are the concentrations of each pollutant? Among biological, physicochemical, or thermal technologies, if physicochemical processes are to be the solution, the treatability of various pollutants must be assessed before a process can be properly designed. This book systematically examines the treatability of hazardous wastes by various physicochemical treatment processes according to the Quantitative Structure–Activity Relationships (QSARs) between kinetic rate constants and molecular descriptors. I have attempted to achieve five major goals in this book: (1) fundamental theories of thermokinetics such as the transition state theory are used to integrate research findings in Advanced Oxidation Process (AOP) research; (2) reaction kinetics and mechanisms for each AOP are explained in terms of elementary reactions and the reactive center; (3) QSARs are introduced as methodologies to assess the treatability of organic compounds; (4) computational molecular descriptors such as the EHOMO and ELUMO are used extensively in the QSAR analysis; (5) the kinetics of various AOPs are compared so that the most effective process can be selected for a given class of organic pollutants. This book is divided into five parts. Chapter 1 to Chapter 4 define the hazardous waste problems and physicochemical approaches to solve these problems. Chapter 5 explains QSAR theory and its application to predicting molecular descriptors and hydroxyl radical reactions. Chapter 6 to Chapter 12 focus on each of the eight most important AOPs. Chapter 13 presents a major reductive treatment technology, zero-valence iron, and Chapter 14 compares each AOP according to its oxidation kinetics for specific classes of organic compounds. Each chapter begins with an introduction of the process and its historical development. The intention is to demonstrate how fundamental sciences guide the search for these innovative technologies. Also, such introductions provide the information necessary for readers to delve into the literature for current research topics. Then, the principles of the process and the degradation kinetics, along with mechanisms of organic
© 2004 by CRC Press LLC
Dedication
In memory of my father, Yuxiang Tang
To my mother, Yongcui Hu, and
To my children, William and Elizabeth,
with love.
© 2004 by CRC Press LLC
相关文档
最新文档